ES2337995T3 - Derivado de amida. - Google Patents

Derivado de amida. Download PDF

Info

Publication number
ES2337995T3
ES2337995T3 ES03738555T ES03738555T ES2337995T3 ES 2337995 T3 ES2337995 T3 ES 2337995T3 ES 03738555 T ES03738555 T ES 03738555T ES 03738555 T ES03738555 T ES 03738555T ES 2337995 T3 ES2337995 T3 ES 2337995T3
Authority
ES
Spain
Prior art keywords
methyl
ylamino
ylmethyl
pyrimidin
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03738555T
Other languages
English (en)
Spanish (es)
Inventor
Tetsuo Asaki
Taisuke Hamamoto
Yukiteru Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30003594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2337995(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of ES2337995T3 publication Critical patent/ES2337995T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES03738555T 2002-06-28 2003-06-27 Derivado de amida. Expired - Lifetime ES2337995T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2002-189269 2002-06-28
JP2002189269 2002-06-28
JP2002-305146 2002-10-18
JP2002305146 2002-10-18
JP2002-377937 2002-12-26
JP2002377937 2002-12-26

Publications (1)

Publication Number Publication Date
ES2337995T3 true ES2337995T3 (es) 2010-05-03

Family

ID=30003594

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03738555T Expired - Lifetime ES2337995T3 (es) 2002-06-28 2003-06-27 Derivado de amida.

Country Status (15)

Country Link
US (1) US7494997B2 (fr)
EP (1) EP1533304B1 (fr)
JP (1) JP4552650B2 (fr)
CN (1) CN100343237C (fr)
AT (1) ATE447560T1 (fr)
AU (1) AU2003246100A1 (fr)
BR (1) BRPI0312288B8 (fr)
CA (1) CA2490907C (fr)
DE (1) DE60329918D1 (fr)
DK (1) DK1533304T3 (fr)
ES (1) ES2337995T3 (fr)
MX (1) MXPA04012845A (fr)
PT (1) PT1533304E (fr)
RU (1) RU2315043C2 (fr)
WO (1) WO2004002963A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7375175B2 (en) 2002-08-19 2008-05-20 National Starch And Chemical Investment Holding Corporation Dispersions containing living radicals
WO2004064743A2 (fr) * 2003-01-17 2004-08-05 Wisconsin Alumni Research Foundation Composes de retinoide modifies et leurs utilisations
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
ATE454152T1 (de) * 2003-06-13 2010-01-15 Novartis Pharma Gmbh 2-aminopyrimidin-derivate als raf-kinase-hemmer
EP1661904A1 (fr) * 2003-08-22 2006-05-31 Meiji Seika Kaisha Ltd. Nouveaux derives d'azalide et d'azalactam et procede permettant de produire ces derives
BRPI0418074B8 (pt) * 2003-12-25 2021-05-25 Nippon Shinyaku Co Ltd derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
AP2470A (en) 2004-09-09 2012-09-17 Natco Pharma Ltd Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
CN101568529A (zh) * 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
EP2166860B1 (fr) 2007-06-07 2016-09-21 Intra-Cellular Therapies, Inc. Nouveaux composés hétérocycliques et utilisations associées
JP5710251B2 (ja) 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規ヘテロ環化合物およびその使用
EP2203436A1 (fr) * 2007-09-17 2010-07-07 Neurosearch A/S Dérivés de pyrazine et leur utilisation en tant que modulateurs des canaux potassiques
WO2009124037A1 (fr) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Procédés de préparation de sunitinib et de sels de ce dernier
KR20110132439A (ko) 2009-03-06 2011-12-07 노파르티스 아게 류신 지퍼- 및 스테릴 알파 모티프-함유 키나제 （ｚａｋ）에 의해 매개된 장애의 치료를 위한 피리미딜아미노벤즈아미드 유도체의 용도
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
JP5948246B2 (ja) 2009-10-23 2016-07-06 ノバルティス アーゲー Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
CN109602734A (zh) * 2012-03-14 2019-04-12 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
NZ746607A (en) 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
US9975878B2 (en) 2013-11-21 2018-05-22 Ptc Therapeutics, Inc. Substituted triazine BMI-1 inhibitors
WO2015076800A1 (fr) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Inhibiteurs de bmi-1 à base de pyridine et de pyrazine substituées
WO2017156350A1 (fr) 2016-03-09 2017-09-14 K-Gen, Inc. Méthodes de traitement du cancer
EP3553057B1 (fr) 2017-01-20 2022-10-26 Shenzhen TargetRx, Inc. Composé (hétéro)arylamide pour inhiber l'activité de la protéine kinase
ES2864405T3 (es) * 2017-01-20 2021-10-13 Shenzhen Targetrx Inc Compuesto de (hetero)arilamida para inhibir la actividad de proteína quinasa
EP3836932A2 (fr) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Méthode de traitement du cancer du pancréas
CN114127065A (zh) * 2019-03-05 2022-03-01 鸿仪有限责任公司 用于治疗神经退行性疾病和癌症的化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (fr) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
JP4552650B2 (ja) 2010-09-29
DK1533304T3 (da) 2010-03-22
US20060014742A1 (en) 2006-01-19
DE60329918D1 (de) 2009-12-17
WO2004002963A1 (fr) 2004-01-08
EP1533304A4 (fr) 2006-10-18
RU2315043C2 (ru) 2008-01-20
EP1533304A1 (fr) 2005-05-25
CN1678590A (zh) 2005-10-05
EP1533304B1 (fr) 2009-11-04
JPWO2004002963A1 (ja) 2005-10-27
BR0312288A (pt) 2005-04-12
CN100343237C (zh) 2007-10-17
AU2003246100A1 (en) 2004-01-19
BRPI0312288B1 (pt) 2019-01-02
BRPI0312288B8 (pt) 2021-05-25
CA2490907A1 (fr) 2004-01-08
RU2005102098A (ru) 2005-09-20
PT1533304E (pt) 2010-02-08
US7494997B2 (en) 2009-02-24
ATE447560T1 (de) 2009-11-15
MXPA04012845A (es) 2005-02-24
CA2490907C (fr) 2010-08-24

Similar Documents

Publication Publication Date Title
ES2337995T3 (es) Derivado de amida.
RU2410375C2 (ru) Амидное производное и лекарственное средство
ES2683127T3 (es) Composiciones útiles para tratar trastornos relacionados con la KIT
CN106883213B (zh) 一种egfr和alk激酶的双重抑制剂
AU2013300344B2 (en) N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer
CN107074866B (zh) 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
ES2418479T3 (es) Antagonistas de la ruta erizo de ftalazinas disustituidas
BRPI0610568A2 (pt) fenilacetamidas adequadas como inibidores de proteìna cinase
AU2007245496A1 (en) Amino-ethyl-amino-aryl (AEAA) compounds and their use
TW200840581A (en) Novel pyrimidine derivatives
ES2796175T3 (es) Compuesto de pirimidina condensado o sal del mismo
JP2024537394A (ja) 修飾タンパク質およびタンパク質分解剤
CN107793417B (zh) 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途
JP2025500871A (ja) ピリミジン又はピリジン誘導体及びその医薬用途
WO2005063720A1 (fr) Derive d'amide et medicament
KR101127725B1 (ko) 아미드 유도체